View : 474 Download: 0
Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study
- Title
- Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study
- Authors
- Kim, Jeongseok; Yoon, Hyuk; Kim, Nayoung; Lee, Kang-Moon; Jung, Sung-Ae; Choi, Chang Hwan; Kim, Eun Soo; Jung, Yunho; Eun, Chang Soo; Kim, Tae Oh; Kang, Sang-Bum; Kim, You Sun; Seo, Geom-Seog; Lee, Chang Kyun; Im, Jong Pil; Park, Soo Jung; Park, Dong Il; Ye, Byong Duk
- Ewha Authors
- 정성애
- SCOPUS Author ID
- 정성애
- Issue Date
- 2021
- Journal Title
- INFLAMMATORY BOWEL DISEASES
- ISSN
- 1078-0998
1536-4844
- Citation
- INFLAMMATORY BOWEL DISEASES vol. 27, no. 12, pp. 1931 - 1941
- Keywords
- vedolizumab; Crohn disease; ulcerative colitis; Korea
- Publisher
- OXFORD UNIV PRESS INC
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background We investigated the real-life effectiveness and safety of vedolizumab (VDZ) induction therapy among Korean patients with Crohn disease (CD) or ulcerative colitis (UC) for whom anti-tumor necrosis factor therapy previously failed. Methods Adult patients who started VDZ induction therapy at 16 centers were prospectively enrolled in the Korean VDZ nationwide registry. The coprimary outcomes were clinical remission, defined as a Crohn's Disease Activity Index score Results Between August 2017 and November 2019, a total of 158 patients (80 with CD and 78 with UC) received VDZ induction therapy. Clinical remission rates among patients with CD and patients with UC were 44.1% and 44.0%, respectively. Among patients with UC, the endoscopic remission rate was 32.4%. Clinical response and remission rates showed increasing trends during induction therapy. Multivariable analysis revealed that clinical response at week 6 was the only predictor of clinical remission at week 14 for both patients with CD and patients with UC. Among patients who experienced 1 or more adverse events (n = 71; 44.9%), disease exacerbation (n = 28; 17.7%) was the most common adverse event. Conclusions Among Korean patients with CD or UC for whom anti-tumor necrosis factor therapy failed, VDZ induction therapy was effective and safe. The early clinical response was associated with clinical remission after VDZ induction therapy.
- DOI
- 10.1093/ibd/izaa361
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML